Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.

New England Journal of Medicine · 11 Nov 2026 · Journal Article

Long, Khattak + more

The abstract is read at the publisher; the summary is JClub's.

In completely resected stage IIB to IV cutaneous melanoma, adding intismeran to pembrolizumab improved 24-month recurrence-free survival to 82.2% versus 70.0% with placebo.

Why it matters: High-risk melanoma after surgery still recurs, and adjuvant strategies are needed to strengthen durable immune control beyond pembrolizumab alone.
What they did: In a phase 3 double-blind trial, 1137 patients received intramuscular intismeran 1 mg or placebo every 3 weeks for nine doses, with pembrolizumab 400 mg every 6 weeks for nine cycles.
The result: Recurrence-free survival and distant-metastasis-free survival were significantly longer with intismeran plus pembrolizumab (24-month: 82.2% vs 70.0%; 88.5% vs 80.2%), with grade 3+ adverse events of 23.6% vs 20.3%.

AI summary of the abstract · may contain errors · not medical advice · read the paper.

1 cited this week

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

Cellular and spatial continuum of TAM functional states governs immune exclusion and dictates immune checkpoint resistance in melanoma.
Genome Medicine · 3 Nov 2026 · Journal Article
AI summary · may contain errors
Lipid-associated TAMs (LA-TAMs) define a macrophage-centered immune neighborhood in melanoma that predicts poor ICI response and survival, linked to immune-excluded architecture.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42983496
Open in JClub
Deep learning reveals prognostic information beyond AJCC stage in routine histopathology of early-stage melanoma: the population-based D-ESMEL study
medRxiv · 30 Oct 2026 · Preprint
AI summary · may contain errors
A deep learning model using routine whole-slide histopathology from early-stage melanoma predicts distant metastatic risk with added prognostic value beyond AJCC stage, achieving a best-fold balanced accuracy of 0.88.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.10.29.26366599
Open in JClub
Immune checkpoint gene-based tumor-immune phenotypes stratify prognosis and immunotherapy-associated remodeling in cutaneous melanoma: a multi-cohort transcriptomic and single-cell re-analysis.
Frontiers in Genetics · 23 Oct 2026 · Journal Article
AI summary · may contain errors
Immune checkpoint gene phenotypes in cutaneous melanoma stratify overall survival, with ICG-high linked to longer survival versus ICG-low (HR 0.34, 95% CI 0.22–0.51).
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42992301
Open in JClub

Journals this month

All journals →

Topics moving, week to 13 Nov 2026

All topics →

By field

All journals by field →

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.

Related in JClub

Cellular and spatial continuum of TAM functional states governs immune exclusion and dictates immune checkpoint resistance in melanoma.

Deep learning reveals prognostic information beyond AJCC stage in routine histopathology of early-stage melanoma: the population-based D-ESMEL study

Immune checkpoint gene-based tumor-immune phenotypes stratify prognosis and immunotherapy-associated remodeling in cutaneous melanoma: a multi-cohort transcriptomic and single-cell re-analysis.

Browse JClub